Submit Your Article CMED MEACR meeting
An official publication of the Middle-Eastern Association for Cancer Research
Clinical Cancer Investigation Journal
ARTICLE
Year: 2022   |   Volume: 11   |   Issue: 4   |   Page: 5-9     View issue

Outcomes and Prognostic Factors in Patients with EGFR Mutant Metastatic Non-Small Cell Lung Cancer Who Treated with Erlotinib


Izzet Dogan, Nijat Khanmammadov, Melin Aydan Ahmed, Anıl Yıldız, Pinar Saip, Adnan Aydiner, Sezai Vatansever
Abstract

The study’s goal is to evaluate the effectiveness of erlotinib in patients with EGFR mutant metastatic non-small cell lung cancer (mNSCLC). The patient's medical data were analyzed retrospectively. Erlotinib's effectiveness was assessed by the radiological response. Survival analyzes were done for prognostic factors. Eighty-five patients were included in the study. 49 (57.6%) of the patients were female, and the average age was 60 (range, 33-85). Exon 19, exon, 21, and other mutations were detected in 62.4%, 24.7%, and 12.9%, respectively. Brain metastases were present in 25.9% and liver metastases in 17.6% of patients. Before erlotinib treatment, 25.9% of the patients received chemotherapy, and 43.5% received radiotherapy. With erlotinib treatment, complete response was found in 15.3%, partial response in 51.8%, and stable response in 10.6% of patients. Median PFS was 22.3 (95% CI, 11.0-33.5) months. Grade 1-2 side effects were observed in 29.1% of the patients, and grade 3-4 side effects in 7.1%. The median OS was found as 37.5 (95% CI, 22.6-52.4) months. The 5-years overall survival rate was found to be 32.2%. In this study, we showed outcomes of erlotinib therapy in patients with EGFR mutant mNSCLC. Erlotinib has been well-tolerated and effective in disease control. Age, number of metastases, and EGFR mutation type predict treatment-related prognosis.

 
Cite this article
Vancouver
Dogan I, Khanmammadov N, Ahmed MA, Yıldız A, Saip P, Aydiner A, et al. Outcomes and Prognostic Factors in Patients with EGFR Mutant Metastatic Non-Small Cell Lung Cancer Who Treated with Erlotinib. Clin Cancer Investig J. 2022;11(4):5-9. https://doi.org/10.51847/rvQeWyfFBI
APA
Dogan, I., Khanmammadov, N., Ahmed, M. A., Yıldız, A., Saip, P., Aydiner, A., & Vatansever, S. (2022). Outcomes and Prognostic Factors in Patients with EGFR Mutant Metastatic Non-Small Cell Lung Cancer Who Treated with Erlotinib. Clinical Cancer Investigation Journal, 11(4), 5-9. https://doi.org/10.51847/rvQeWyfFBI

Downloads: 8

Views: 18
Sitemap | What's New | Feedback | Copyright and Disclaimer | Privacy Notice
© Clinical Cancer Investigation Journal | Published by Polaris Publication
Online since 01 December, 2011
Editorial and Ethics Policies
Creative Commons  Open Access Journal View mobile site 
ISSN: Print -2278-1668, Online - 2278-0513